EXPErimental medicine Route To Success in Amyotrophic Lateral Sclerosis (EXPERTS-ALS)

Research summary

The EXPERTS-ALS platform is designed as a randomised,open-label,multi-arm trial with a biomarker-based endpoint. It aims to prioritise drugs for further testing based on their ability to lower NFL levels and to also identify drug-specific adverse events.The EXPERTS-ALS protocol describes an overarching trial design to evaluate the effect of candidate drugs on blood NFL levels in patients with ALS receiving usual standard of care. The protocol is deliberately flexible,allowing: as broad a range of ALS patients to be recruited; participant randomisation between only those treatment arms that are not believed by the enrolling doctor to be contraindicated (e.g. by particular co-morbid conditions or concomitant medications); and treatment arms to be added or removed according to the emerging evidence from within the trial.

Principal Investigator

Prof Martin Turner

Contact us

Email: dendron@ouh.nhs.uk

IRAS number

1007791